Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Monoclonal Antibodies and Their Functional Fragments in Research, Diagnosis and Therapy
| Monoclonal Antibodies and Their Functional Fragments in Research, Diagnosis and Therapy |
| Autore | Ruvo Menotti |
| Pubbl/distr/stampa | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
| Descrizione fisica | 1 electronic resource (278 p.) |
| Soggetto topico | Technology: general issues |
| Soggetto non controllato |
porcine deltacoronavirus
nucleocapsid monoclonal antibodies neurodegenerative disorders affibody molecules blood–brain barrier receptor-mediated transcytosis transferrin receptor AL amyloidosis CD38 anti-CD38 MoAb Daratumumab Isatuximab myeloma BCMA bispecific T-cell engager antibody-drug conjugates chimeric antigen receptor T-cells belantamab mafodotin idecabtagene vicleucel JNJ-68284528 Mabs Antibody-Drug Conjugate cancer therapy drug targeting payload cross-linking antibody fragment Fab scFv E. coli YKL-40 CHI3L1 monoclonal antibody phage display lung metastasis prostate-specific membrane antigen in vivo imaging prostate cancer glutamate carboxypeptidase II NAALADase immunization antibody protocol guinea pig cDNA chimeric antigen receptor (CAR T) universal CAR T modular CAR T universal immune receptor CAR adaptor adoptive immunotherapy split CAR bispecific polyspecificity pharmacokinetics solubility aggregation viscosity developability stability affinity specificity protein engineering self-association non-specific binding immunogenicity antibody fragments single chain amyloid oligomer neurotoxicity NUsc1 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557613003321 |
Ruvo Menotti
|
||
| Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Mycobacterium tuberculosis Pathogenesis, Infection Prevention and Treatment
| Mycobacterium tuberculosis Pathogenesis, Infection Prevention and Treatment |
| Autore | Ferraris Davide Maria |
| Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 |
| Descrizione fisica | 1 electronic resource (128 p.) |
| Soggetto topico |
Research & information: general
Biology, life sciences |
| Soggetto non controllato |
Mycobacterium tuberculosis
line probe assay second-line drugs drug resistance XDR-TB MDR-TB omics analysis TB treatment system analysis Beijing B0/W148 Mycobacterium smegmatis imidazo[1,2-b][1,2,4,5]tetrazine MmpS5-MmpL5 efflux drug discovery tuberculosis immune activation HLA-DR CD38 treatment response Mycobacterium macrophage apoptosis effector cytokine microRNA Beijing genotype Central Asia Outbreak murine infection model Virulence pre-XDR-TB Mycobacterium avium unique metabolic pathways subtractive genomics drug target uncharacterized proteins BM-MSCs Mtb bone-homing stem cell niche latent tuberculosis relapse liposomes M. tuberculosis host-pathogen interactions immune response antitubercular drug discovery antitubercular treatments IL-18 IL-18BP IL-18R gene expression |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557291103321 |
|
Ferraris Davide Maria
|
||
| Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
New Insights into the Pathogenesis and Therapies of IgA Nephropathy
| New Insights into the Pathogenesis and Therapies of IgA Nephropathy |
| Autore | Suzuki Hitoshi |
| Pubbl/distr/stampa | Basel, : MDPI Books, 2022 |
| Descrizione fisica | 1 electronic resource (194 p.) |
| Soggetto topico | Medicine |
| Soggetto non controllato |
obesity
mesangial matrix expansion body mass index IgA nephropathy IgA Vasculitis IgA Nephropathy adults children presentation physiopathology genetics prognosis treatment IgA clinical trials kidney mesangium mouse model aberrantly glycosylated IgA1 galactose-deficient IgA1 glycosylation of IgA1 biomarker complement C3 O-glycosylation IgA1 autoantibody immune complex complement kidney nephrology IgA vasculitis nephritis kidney biopsy plasma cells CD38 renal pathology urinary galactose-deficient IgA1 KM55 crescents proteinuria glomerular filtration rate Oxford score |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910595072403321 |
|
Suzuki Hitoshi
|
||
| Basel, : MDPI Books, 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Targeting STAT3 and STAT5 in Cancer
| Targeting STAT3 and STAT5 in Cancer |
| Autore | Moriggl Richard |
| Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 |
| Descrizione fisica | 1 electronic resource (578 p.) |
| Soggetto topico |
Research & information: general
Biology, life sciences |
| Soggetto non controllato |
multiple myeloma
STAT3 S3I-1757 nanoparticle CD38 siRNA/RNAi polyethylenimine PEI lipopolyplex siRNA delivery glioma glioblastoma STAT5 AKT ERK1/2 prolactin androgens prostate cancer knockout escape mechanisms stem/progenitor cells cell hierarchy cancer CD4+ T cells CD8+ T cells myeloid cells immune check point hepatitis C virus (HCV) cirrhosis hepatocellular carcinoma (HCC) endoplasmic reticulum (ER) stress oxidative stress (OS) unfolded protein response (UPR) microRNA-122 (miR-122) nuclear factor erythroid 2-related factor 2 (NRF2) signal transducer and activator of transcription 3 (STAT3) hepatocyte nuclear factor 4 alpha (HNF4A) solid cancers cell cycle apoptosis inflammation mitochondria stemness tumor suppression melanoma autoimmune disease immunotherapy tumor-immune cell interactions breast cancer PD-L1 M2 macrophages NK cells STAT3 inhibitor XIII hedging transaction costs dynamic programming risk management post-decision state variable cancer progression cancer-stem cell cytokine therapy resistance metastasis immunosuppression tumor microenvironment proliferation tyrosine kinase 2 JAK family of protein tyrosine kinases signal transducer and activator of transcription cytokine receptor signaling gain-of-function mutation tumorigenesis ADAM17 interleukin-6 trans-signaling epidermal growth factor receptor (EGF-R) shedding metalloprotease tumor necrosis factor alpha (TNFα) inflammation associated cancer colon cancer lung cancer SH2 domain mutations autosomal-dominant hyper IgE syndrome inflammatory hepatocellular adenomas T-cell large granular lymphocytic leukemia T-cell prolymphocytic leukemia growth hormone insensitivity syndrome nuclear pore complex nuclear transport receptors nucleocytoplasmic shuttling targeting tumor-associated macrophages adoptive T cell therapy immune suppression STAT transcription factors JAK STAT T-PLL T-cell leukemia meta-analysis STAT5B signaling small-molecule inhibitors cancer models companion animals comparative oncology pharmacological inhibitor STAT5 signaling chemotherapy resistance myeloid leukemia heat shock proteins chaperones stabilization targeted therapy ovarian cancer hematopoietic cancers therapeutic targeting pharmacological inhibitors mTOR Bone Marrow Failure Syndromes lymphocytes lymphoma T-cells RHOA NGS MPN JAK2 V617F neoplastic stem cells |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557623503321 |
|
Moriggl Richard
|
||
| Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||